- Citi’s 15th Annual
Biopharma Virtual Conference. Susan M. Molineaux, Ph.D., the company’s founder, president and chief executive officer, will participate in a panel presentation titled “Precision Targeted Drugs in Oncology,” on Wednesday, September 9, 2020, at 11:40 a.m. Eastern Time.
Wells Fargo Virtual Healthcare Conference. Susan M. Molineauxwill participate in an analyst moderated meeting on Thursday, September 10, 2020, at 11:20 a.m. Eastern Time. H.C. Wainwright & Co.22nd Annual Global Investment Conference. Susan M. Molineauxwill present on Wednesday, September 16, 2020, at 9:30 a.m. Eastern Time. Cantor Virtual Global Healthcare Conference2020. Susan M. Molineauxwill present on Thursday, September 17, 2020, at 2:40 p.m. Eastern Time.
The presentations will be webcast live and also available for replay for up to 30 days following initial presentation in the Investor Relations section at www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the
SOURCE: Calithera Biosciences, Incorporated
Source: Calithera Biosciences, Inc.